Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis
- PMID: 17401513
- DOI: 10.1007/s10067-007-0613-2
Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis
Abstract
Oxidative stress is involved in pathogenesis of Raynaud's phenomenon (RP), a hallmark of systemic sclerosis (SSc). Frequent episodes of ischemia-reperfusion may lead to release of free radicals and enhanced lipid peroxidation reflected by elevated levels of malondialdehyde (MDA). The failure of native antioxidants (Catalase [CAT], Superoxide dismutase [SOD], and Ceruloplasmin [CP]) might be crucial in endothelial cells damage in RP. Iloprost (IL) synthetic prostacyclin analogue is currently used in the treatment of SSc patients with RP. The objectives of this study were to compare the serum levels of MDA and CP, CAT and SOD activity in red blood cells hemolysate in SSc patients compared to healthy controls; and to study the effect of 5-days IL infusions on MDA and CP levels, and CAT and SOD activity in SSc patients with RP. Twelve SSc patients were treated with 50 mug IL for 5 days. Blood samples were taken before and after day 1st and after day 5th of IL infusions. Levels of CAT were measured according to the Aebi's method; SOD, according to the Misra and Fridovich method; MDA, according to Slater's method; and CP, according to Ravin's method. Activities of CAT (p < 0.001) and SOD (p < 0.04) were significantly reduced; levels of CP (p < 0.006) and MDA (p < 0.06) were raised in SSc compared to controls. IL infusions caused reduction in MDA (p < 0.0001) levels and enhanced production of SOD (p < 0.006) and CAT (p < 0.003). The levels of CP did not change (p = 0.48). Oxidant status in SSc patients with RP is impaired. Therapy with IL led to normalization of antioxidant activity. We suggest that CAT may be a sensitive and reliable laboratory marker of oxidative stress severity in RP. We found that IL, in addition to its vasoactive properties, has a potential to activate inner antioxidant system. Activation of inner antioxidant activity may explain long-term effect of IL instead of its very short half-life time.
Similar articles
-
Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.Acta Derm Venereol. 2001 Aug-Sep;81(4):294-7. doi: 10.1080/00015550152572976. Acta Derm Venereol. 2001. PMID: 11720181
-
Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.Clin Exp Rheumatol. 2001 Sep-Oct;19(5):503-8. Clin Exp Rheumatol. 2001. PMID: 11579708 Clinical Trial.
-
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.Arthritis Rheum. 1998 Apr;41(4):670-7. doi: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I. Arthritis Rheum. 1998. PMID: 9550476 Clinical Trial.
-
Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.Semin Arthritis Rheum. 2019 Feb;48(4):686-693. doi: 10.1016/j.semarthrit.2018.03.019. Epub 2018 Apr 4. Semin Arthritis Rheum. 2019. PMID: 29706243
-
The cardiac magnetic resonance in the diagnosis of cardiac Raynaud phenomenon in a patient with systemic sclerosis: case report and review of literature.Expert Rev Clin Immunol. 2016;12(3):251-5. doi: 10.1586/1744666X.2016.1134320. Epub 2016 Jan 6. Expert Rev Clin Immunol. 2016. PMID: 26692357 Review.
Cited by
-
Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.J Proteomics. 2021 Jun 30;242:104243. doi: 10.1016/j.jprot.2021.104243. Epub 2021 Apr 27. J Proteomics. 2021. PMID: 33930553 Free PMC article.
-
Plasma biomarkers of endothelial function, inflammation and oxidative stress in individuals with non-freezing cold injury.Exp Physiol. 2023 Mar;108(3):448-464. doi: 10.1113/EP090722. Epub 2023 Feb 20. Exp Physiol. 2023. PMID: 36808666 Free PMC article.
-
Recent advances in the treatment of systemic sclerosis.Clin Rev Allergy Immunol. 2009 Jun;36(2-3):176-200. doi: 10.1007/s12016-008-8114-x. Clin Rev Allergy Immunol. 2009. PMID: 19132559 Review.
-
Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.Eur J Med Res. 2014 Jan 10;19(1):2. doi: 10.1186/2047-783X-19-2. Eur J Med Res. 2014. PMID: 24410934 Free PMC article. Clinical Trial.
-
Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.Acta Biomed. 2023 Aug 3;94(4):e2023148. doi: 10.23750/abm.v94i4.14317. Acta Biomed. 2023. PMID: 37539603 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous